Aethlon jumps on positive results from in vitro binding study of Hemopurifier device
Seeking Alpha News (Fri, 10-May 9:13 AM ET)
PRNewswire (Fri, 10-May 8:01 AM ET)
PRNewswire (Wed, 21-Feb 8:01 AM ET)
Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update
PRNewswire (Wed, 14-Feb 4:15 PM ET)
Aethlon Medical Inc is a medical technology company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
Aethlon Medical trades on the NASDAQ stock market under the symbol AEMD.
As of May 13, 2024, AEMD stock price declined to $0.99 with 1,448,138 million shares trading.
AEMD has a market cap of $2.61 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, AEMD stock traded as high as $124.90 and as low as $.98.
The top ETF exchange traded funds that AEMD belongs to (by Net Assets): VXF.
AEMD has underperformed the market in the last year with a price return of -69.0% while the SPY ETF gained +28.2%. AEMD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -42.5% and -27.5%, respectively, while the SPY returned +5.8% and +2.1%, respectively.
AEMD support price is $1.11 and resistance is $1.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AEMD stock will trade within this expected range on the day.